Baupost Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-25,791,678
| Closed | -$87.7M | – | 42 |
|
|
2018
Q3 | $87.7M | Hold |
25,791,678
| – | – | 0.67% | 24 |
|
|
2018
Q2 | $97M | Hold |
25,791,678
| – | – | 0.85% | 21 |
|
|
2018
Q1 | $105M | Hold |
25,791,678
| – | – | 1.02% | 20 |
|
|
2017
Q4 | $120M | Hold |
25,791,678
| – | – | 1.19% | 18 |
|
|
2017
Q3 | $183M | Hold |
25,791,678
| – | – | 2.28% | 13 |
|
|
2017
Q2 | $186M | Hold |
25,791,678
| – | – | 2.13% | 14 |
|
|
2017
Q1 | $159M | Hold |
25,791,678
| – | – | 1.87% | 15 |
|
|
2016
Q4 | $151M | Hold |
25,791,678
| – | – | 1.97% | 15 |
|
|
2016
Q3 | $137M | Hold |
25,791,678
| – | – | 1.95% | 14 |
|
|
2016
Q2 | $171M | Hold |
25,791,678
| – | – | 2.32% | 13 |
|
|
2016
Q1 | $120M | Hold |
25,791,678
| – | – | 1.74% | 13 |
|
|
2015
Q4 | $130M | Hold |
25,791,678
| – | – | 2.36% | 10 |
|
|
2015
Q3 | $84.5M | Hold |
25,791,678
| – | – | 1.41% | 18 |
|
|
2015
Q2 | $257M | Buy |
25,791,678
+3,411,478
| +15% | +$36.6M | 4.29% | 9 |
|
|
2015
Q1 | $285M | Buy |
22,380,200
+4,080,200
| +22% | +$52.5M | 4.79% | 9 |
|
|
2014
Q4 | $259M | Hold |
18,300,000
| – | – | 5.09% | 7 |
|
|
2014
Q3 | $252M | Buy |
18,300,000
+7,760,014
| +74% | +$119M | 4.38% | 6 |
|
|
2014
Q2 | $162M | Buy |
10,539,986
+4,229,136
| +67% | +$59.9M | 2.64% | 8 |
|
|
2014
Q1 | $108M | Buy |
+6,310,850
| New | +$95.2M | 2.6% | 8 |
|
Baupost Group's KERX Position: Q4 2018 in Review
Baupost Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 25,791,678 shares — an estimated $87.7M sold.
Baupost Group first reported a position in KERX in Q1 2014 and held it in 19 quarters. The position peaked at $285M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Baupost Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Baupost Group sold 25,791,678 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $87.7M.
- Baupost Group first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 19 quarters.
- Baupost Group's Keryx Biopharmaceuticals Inc position peaked at $285M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Baupost Group's 13F filing for Q4 2018, filed 13 Feb 2019.